Bonus BioGroup Ltd. Logo

Bonus BioGroup Ltd.

Develops cell therapies and tissue products for bone grafts and inflammation repair.

BONS | TA

Overview

Corporate Details

ISIN(s):
IL0004850116
LEI:
Country:
Israel
Address:
Park P.O.B 15143, 31905 Haifa
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Bonus BioGroup Ltd. is a clinical-stage biotechnology company specializing in regenerative medicine. The company develops investigational cell therapy and tissue engineering products to address unmet medical needs related to tissue damage, inflammation, and bone loss. Its pipeline is led by two key candidates: BonoFill, a personalized, viable bone graft engineered from a patient's own cells for orthopedic and maxillofacial applications; and MesenCure, an allogeneic cell therapy designed to target inflammation and promote tissue repair. These therapies are currently being evaluated in clinical trials for safety and efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-27 11:48
Investor Presentation
Company Presentation- 2025
Hebrew (modern) 9.0 MB
2025-05-27 11:48
Regulatory Filings
Company Presentation- 2025
Russian 43.6 KB
2023-07-11 12:06
Investor Presentation
Company Presentation, July 2023
English 3.4 MB
2023-07-11 12:06
Investor Presentation
Company Presentation, July 2023
Russian 44.7 KB
2022-04-11 16:02
Investor Presentation
Company Presentation
English 8.2 MB
2022-04-11 16:02
Registration Form
Company Presentation
Russian 47.1 KB
2022-04-11 15:01
Investor Presentation
Company Presentation
Hebrew (modern) 11.0 MB
2022-04-11 15:01
Pre-Annual General Meeting Information
Company Presentation
Russian 47.1 KB
2022-01-10 10:52
Regulatory Filings
The company inteds to publish an immediate report, trading will be open after …
Hebrew (modern) 105.1 KB

Automate Your Workflow. Get a real-time feed of all Bonus BioGroup Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bonus BioGroup Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bonus BioGroup Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland
ACHI
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG

Talk to a Data Expert

Have a question? We'll get back to you promptly.